Digital Therapeutics
Digital therapeutics (DTx) are digital interventions with clearance from a regulatory body to prevent, manage and treat a disorder or disease aiming for a clinical outcome.
Our therapeutic focus areas: Nephrology & Cardiology
-
Chronic kidney disease (CKD) affects several hundred million patients globally and 3+ mio. patients globally undergo regular dialysis treatments due to end-stage-renal-disease (ESRD)
-
In most countries, cardiovascular diseases are the leading cause of death and single largest medical speciality in terms of payer spending on healthcare
-
We are developing the go-to digital therapeutics toolkit for slowing down CKD progression, delaying the start of dialysis and avoiding serious medical complications in dialysis care. Additionally, we are tackling key cardiac diseases, including heart insufficiency, hypertension and arrhythmia.
Phase 1
Exploration
Phase 1
Exploration
Phase 1
Exploration
Phase 2
Design & POC
Our DTx product pipeline
Nephrology
Hypervolemia
CX Miku 501
Hypertension
CX Miku 502
Hyperphosphatemia
CX Miku 503
Hyperkalemia
CX Miku 504
CKD Prevention
CX Miku 340
ESRD Delay
CX Miku 450
Phase 1
Exploration
Phase 2
Design & POC
Phase 3
Pivotal Trial
Phase 4
Regulatory
Phase 5
Launch
Cardiology
Heart Insufficiency
CX 101
Hypertension
CX 102
Hypertension
CX 102
The patient companion app for chronic kidney disease is now widely available!
We are currently developing the first suite of digital therapeutics for dialysis patients to expand MIKU’s product offering.
